相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain
Susanne Grunewald et al.
CANCER DISCOVERY (2021)
Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib
John Nemunaitis et al.
FUTURE ONCOLOGY (2020)
PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis (SM) With Symptoms Inadequately Controlled by Standard Therapy
Cem Akin et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
Jean-Yves Blay et al.
LANCET ONCOLOGY (2020)
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
Michael C Heinrich et al.
LANCET ONCOLOGY (2020)
Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib
Filip Janku et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pure Pathologic Response Is Associated with Improved Overall Survival in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib in the Phase I EXPLORER Study
Jason Gotlib et al.
BLOOD (2020)
Rational Drug Design Approach of Receptor Tyrosine Kinase Type III Inhibitors
Cheolhee Kim et al.
CURRENT MEDICINAL CHEMISTRY (2019)
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
Cesar Serrano et al.
BRITISH JOURNAL OF CANCER (2019)
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
Bryan D. Smith et al.
CANCER CELL (2019)
Cutaneous Melanoma Version 2.2019
Daniel G. Coit et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies
Ellen Weisberg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT
Beth Apsel Winger et al.
CANCER RESEARCH (2019)
Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management
Animesh Pardanani
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry
Jerry W. Call et al.
CLINICAL SARCOMA RESEARCH (2019)
Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial
D. J. DeAngelo et al.
LEUKEMIA (2018)
Long-Term Outcome of Dasatinib First-Line Treatment in Gastrointestinal Stromal Tumor: A Multicenter, 2-Stage Phase 2 Trial (Swiss Group for Clinical Cancer Research 56/07)
Michael Montemurro et al.
CANCER (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases
Lillian R. Klug et al.
PHARMACOLOGY & THERAPEUTICS (2018)
FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis
Yvette L. Kasamon et al.
ONCOLOGIST (2018)
Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors
Amber E. Bannon et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2017)
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels
Paolo G. Casali et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Andreas Hochhaus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A precision therapy against cancers driven by KIT/PDGFRA mutations
Erica K. Evans et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results Analysis of Phase 3 SWOG Intergroup Trial S0033
Michael C. Heinrich et al.
JAMA ONCOLOGY (2017)
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+advanced systemic mastocytosis
M. Jawhar et al.
LEUKEMIA (2016)
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis
Jason Gotlib et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial
Jean-Yves Blay et al.
LANCET ONCOLOGY (2015)
KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis
M. Arock et al.
LEUKEMIA (2015)
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
Garrett M. Frampton et al.
CANCER DISCOVERY (2015)
The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis
Philipp Erben et al.
ANNALS OF HEMATOLOGY (2014)
Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients
Andrew P. Garner et al.
CLINICAL CANCER RESEARCH (2014)
A phase 2 study of ponatinib in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after failure of tyrosine kinase inhibitor (TKI) therapy: Initial report.
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis
M. Montemurro et al.
EUROPEAN JOURNAL OF CANCER (2013)
Gastrointestinal Stromal Tumors Molecular Markers and Genetic Subtypes
Christine M. Barnett et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2013)
Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri et al.
LANCET (2013)
Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation
Y. Bai et al.
LEUKEMIA (2013)
Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
C. Cauchi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group
S. H. Park et al.
INVESTIGATIONAL NEW DRUGS (2012)
Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial
Suzanne George et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036
Wayne W. Chan et al.
CANCER CELL (2011)
The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile
Christopher A. Eide et al.
CANCER RESEARCH (2011)
Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification
Jun Guo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Improved Detection of the KIT D816V Mutation in Patients with Systemic Mastocytosis Using a Quantitative and Highly Sensitive Real-Time qPCR Assay
Thomas Kristensen et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2011)
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis
Celalettin Ustun et al.
LEUKEMIA RESEARCH (2011)
Gastrointestinal stromal tumours: origin and molecular oncology
Christopher L. Corless et al.
NATURE REVIEWS CANCER (2011)
Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
D. Handolias et al.
BRITISH JOURNAL OF CANCER (2010)
Activation State-Dependent Binding of Small Molecule Kinase Inhibitors: Structural Insights from Biochemistry
Lisa M. Wodicka et al.
CHEMISTRY & BIOLOGY (2010)
Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients
Martine Van Glabbeke
JOURNAL OF CLINICAL ONCOLOGY (2010)
Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure
George D. Demetri et al.
CLINICAL CANCER RESEARCH (2009)
Structural biology contributions to tyrosine kinase drug discovery
Sandra W. Cowan-Jacob et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib
M. Montemurro et al.
EUROPEAN JOURNAL OF CANCER (2009)
A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: The AFR-15 trial
Patrice Chevallier et al.
LEUKEMIA RESEARCH (2009)
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis
Arturo Vega-Ruiz et al.
LEUKEMIA RESEARCH (2009)
Phase II trial of imatinib mesylate in patients with metastatic melanoma
K. B. Kim et al.
BRITISH JOURNAL OF CANCER (2008)
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases
Michael C. Heinrich et al.
CLINICAL CANCER RESEARCH (2008)
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis
Srdan Verstovsek et al.
CLINICAL CANCER RESEARCH (2008)
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Heterogeneity of kinase inhibitor resistance mechanisms in GIST
B. Liegl et al.
JOURNAL OF PATHOLOGY (2008)
Results of a multicenter phase II trial for older patients with c-kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose ara-C and imatinib
Florian Heidel et al.
CANCER (2007)
Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
Vicki L. Goodman et al.
CLINICAL CANCER RESEARCH (2007)
Food and drug administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma
Edwin P. Rock et al.
ONCOLOGIST (2007)
Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia
Christopher L. Corless et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2006)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: Enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling
Takayuki Ikezoe et al.
CANCER SCIENCE (2006)
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis
Neil P. Shah et al.
BLOOD (2006)
Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma - Significant toxicity with no clinical efficacy
K Wyman et al.
CANCER (2006)
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
Maria Debiec-Rychter et al.
EUROPEAN JOURNAL OF CANCER (2006)
Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate
H Prenen et al.
CLINICAL CANCER RESEARCH (2006)
A novel K5091 mutation of KIT identified in familial mastocytosis -: in vitro and in vivo responsiveness to imatinib therapy
LY Zhang et al.
LEUKEMIA RESEARCH (2006)
Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate
E Wardelmann et al.
CLINICAL CANCER RESEARCH (2006)
Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT
LH Einhorn et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2006)
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT:: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects
KV Gleixner et al.
BLOOD (2006)
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT Isoforms associated with human malignancies
MM Schittenhelm et al.
CANCER RESEARCH (2006)
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation
J Gotlib et al.
BLOOD (2005)
Molecular modeling of wild-type and D816V c-kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases
J Vendôme et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Activation mutations of human c-KIT resistant to imatinib, mesylate are sensitive to the tyrosine kinase inhibitor PKC412
JD Growney et al.
BLOOD (2005)
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation
CR Antonescu et al.
CLINICAL CANCER RESEARCH (2005)
Lack of clinical efficacy of imatinib in metastatic melanoma
S Ugurel et al.
BRITISH JOURNAL OF CANCER (2005)
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants
M Debiec-Rychter et al.
GASTROENTEROLOGY (2005)
A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib
C Akin et al.
BLOOD (2004)
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group
M Debiec-Rychter et al.
EUROPEAN JOURNAL OF CANCER (2004)
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
J Verweij et al.
LANCET (2004)
Biology of gastrointestinal stromal tumors
CL Corless et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors
LL Chen et al.
CANCER RESEARCH (2004)
Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase
CD Mol et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient
E Tamborini et al.
GASTROENTEROLOGY (2004)
Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia
T Kindler et al.
BLOOD (2004)
UCSF chimera - A visualization system for exploratory research and analysis
EF Pettersen et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2004)
High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib
HK Al-Ali et al.
HEMATOLOGY JOURNAL (2004)
Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders
A Pardanani et al.
LEUKEMIA RESEARCH (2004)
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
MC Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors
S Hirota et al.
GASTROENTEROLOGY (2003)
Imatinib for systemic mast-cell disease
A Pardanani et al.
LANCET (2003)
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
S Branford et al.
BLOOD (2003)
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders
J Cortes et al.
CANCER (2003)
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
J Cools et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
PDGFRA activating mutations in gastrointestinal stromal tumors
MC Heinrich et al.
SCIENCE (2003)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
NP Shah et al.
CANCER CELL (2002)
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
S Branford et al.
BLOOD (2002)
Clinical management of gastrointestinal stromal tumors: Before and after STI-571
RP DeMatteo et al.
HUMAN PATHOLOGY (2002)
Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies
MC Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a phase I study
AT van Oosterom et al.
LANCET (2001)
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications
DA Tuveson et al.
ONCOGENE (2001)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
T Schindler et al.
SCIENCE (2000)
KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors
ML Lux et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
分享论文
